Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report

J Clin Pharm Ther. 2021 Aug;46(4):1185-1187. doi: 10.1111/jcpt.13411. Epub 2021 Jun 10.

Abstract

What is known and objective: Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered.

Case description: A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was started to ensure he was on three active HIV medications.

What is new and conclusion: Ibalizumab-uiyk has no known drug-drug interactions and may be used as bridge therapy for patients with drug-resistant HIV undergoing chemotherapy.

Keywords: AIDS; HIV and lymphoma; diffuse large B-cell lymphoma; drug-drug interaction chemotherapy and antiretroviral therapy; drug-resistant HIV-1 infection; ibalizumab-uiyk.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Drug Interactions
  • Drug Resistance, Viral
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / complications*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Male

Substances

  • Anti-HIV Agents
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • ibalizumab